Clinical Trials
28 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
INDIGO
Boston Scientific Corporation
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
POLMS
Azienda USL Reggio Emilia - IRCCS
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
inMMyCAR
Kelonia Therapeutics, Inc.
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK
VIRO-25
Genelux Corporation
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Novartis
intERsection
Hospital Universitario 12 de Octubre
uTRACT
UroGen Pharma Ltd.
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Shenzhen University General Hospital
ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma
University Hospital Muenster
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
OriCell Therapeutics Co., Ltd.
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
Regionshospitalet Silkeborg
SEPTRALU
Sociedad Española de Medicina Nuclear e Imagen Molecular
ALTER-E005
Jiangxi Provincial Cancer Hospital
Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%
Shanghai Pulmonary Hospital, Shanghai, China